Eli Lilly and (NYSE:LLY – Get Rating) issued its quarterly earnings results on Thursday. The company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.86 by ($0.61), Briefing.com reports. Eli Lilly and had a return on equity of 97.58% and a net margin of 20.90%. The firm had revenue of $6.49 billion during the quarter, compared to analysts’ expectations of $6.85 billion. During the same quarter in the prior year, the firm earned $1.87 EPS. The firm’s revenue was down 3.7% compared to the same quarter last year. Eli Lilly and updated its FY 2022 guidance to $7.90-$8.05 EPS.
Eli Lilly and Stock Performance
Shares of Eli Lilly and stock traded down $4.47 during trading hours on Friday, hitting $301.32. 2,805,792 shares of the company’s stock traded hands, compared to its average volume of 2,923,813. Eli Lilly and has a 12-month low of $220.20 and a 12-month high of $335.33. The stock has a market capitalization of $286.30 billion, a price-to-earnings ratio of 44.64, a PEG ratio of 2.22 and a beta of 0.35. The company has a fifty day simple moving average of $316.10 and a 200-day simple moving average of $289.01. The company has a debt-to-equity ratio of 1.60, a current ratio of 1.27 and a quick ratio of 0.98.
Eli Lilly and Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Monday, August 15th will be given a dividend of $0.98 per share. This represents a $3.92 annualized dividend and a dividend yield of 1.30%. The ex-dividend date is Friday, August 12th. Eli Lilly and’s dividend payout ratio is presently 58.07%.
Institutional Trading of Eli Lilly and
Large investors have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership raised its holdings in shares of Eli Lilly and by 54.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,311,713 shares of the company’s stock valued at $948,375,000 after buying an additional 1,172,504 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Eli Lilly and by 2.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,869,274 shares of the company’s stock valued at $1,108,044,000 after buying an additional 83,299 shares in the last quarter. Worldquant Millennium Advisors LLC increased its stake in Eli Lilly and by 587.1% in the 1st quarter. Worldquant Millennium Advisors LLC now owns 64,860 shares of the company’s stock worth $18,574,000 after purchasing an additional 55,421 shares during the period. Sculptor Capital LP increased its stake in Eli Lilly and by 61.1% in the 1st quarter. Sculptor Capital LP now owns 144,343 shares of the company’s stock worth $41,336,000 after purchasing an additional 54,722 shares during the period. Finally, Edgestream Partners L.P. increased its stake in Eli Lilly and by 399.9% in the 1st quarter. Edgestream Partners L.P. now owns 24,486 shares of the company’s stock worth $7,012,000 after purchasing an additional 19,588 shares during the period. Institutional investors own 82.75% of the company’s stock.
Wall Street Analyst Weigh In
LLY has been the topic of several research analyst reports. Morgan Stanley boosted their target price on shares of Eli Lilly and from $369.00 to $395.00 and gave the stock an “overweight” rating in a research report on Friday, July 8th. UBS Group raised their price objective on Eli Lilly and to $335.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 27th. The Goldman Sachs Group raised their price target on Eli Lilly and from $234.00 to $264.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. JPMorgan Chase & Co. raised their price objective on Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. Finally, Wells Fargo & Company upped their price objective on shares of Eli Lilly and from $280.00 to $305.00 in a report on Friday, April 29th. Three research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $316.06.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
- BJ’s Wholesale Club Stock Has More Room to Grow
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.